Genomes and Genes

Species

Haruyasu Murakami

Summary

Affiliation: Shizuoka Cancer Center
Country: Japan

Publications

  1. request reprint
    Murakami H, Ono A, Takahashi T, Onozawa Y, Tsushima T, Yamazaki K, et al. Phase I study of Efatutazone, an oral PPARγ agonist, in patients with metastatic solid tumors. Anticancer Res. 2014;34:5133-41 pubmed
    ..RD was determined to be 0.50 mg bid, corresponding to the RD in previous global phase I studies. Efatutazone demonstrated acceptable toxicity and gave evidence of disease control in Japanese patients with metastatic solid tumors. ..
  2. Akamatsu H, Ono A, Shukuya T, Tsuya A, Nakamura Y, Kenmotsu H, et al. Disease flare after gefitinib discontinuation. Respir Investig. 2015;53:68-72 pubmed publisher
    ..Our analysis demonstrated a lower incidence rate of disease flare after gefitinib discontinuation compared with the previous report, but the prognosis was similarly poor. ..
  3. Murakami H, Ikeda M, Okusaka T, Inaba Y, Iguchi H, Yagawa K, et al. A Phase I study of MEDI-575, a PDGFRα monoclonal antibody, in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol. 2015;76:631-9 pubmed publisher
    ..MEDI-575 once weekly and 3-weekly was well tolerated with a favorable pharmacokinetic profile in Japanese patients with advanced solid tumors. ClinicalTrials.gov, NCT01102400. ..
  4. Nishio M, Horiike A, Murakami H, Yamamoto N, Kaneda H, Nakagawa K, et al. Phase I study of the HER3-targeted antibody patritumab (U3-1287) combined with erlotinib in Japanese patients with non-small cell lung cancer. Lung Cancer. 2015;88:275-81 pubmed publisher
    ..Patritumab in combination with erlotinib was well tolerated and the efficacy of the combination was encouraging, especially in patients where prior gefitinib treatment failed. ..
  5. Naito T, Okayama T, Aoyama T, Ohashi T, Masuda Y, Kimura M, et al. Unfavorable impact of cancer cachexia on activity of daily living and need for inpatient care in elderly patients with advanced non-small-cell lung cancer in Japan: a prospective longitudinal observational study. BMC Cancer. 2017;17:800 pubmed publisher
    ..Trial registration number: UMIN000009768 . Name of registry: UMIN (University hospital Medical Information Network). Date of registration: 14 January 2013. Date of enrolment of the first participant to the trial: 23 January 2013. ..
  6. Naito T, Okayama T, Aoyama T, Ohashi T, Masuda Y, Kimura M, et al. Skeletal muscle depletion during chemotherapy has a large impact on physical function in elderly Japanese patients with advanced non-small-cell lung cancer. BMC Cancer. 2017;17:571 pubmed publisher
    ..URL of registry: Date of registration: 14 January 2013. Date of enrolment of the first participant to the trial: 23 January 2013. ..
  7. Ono A, Takahashi T, Mori K, Akamatsu H, Shukuya T, Taira T, et al. Prognostic impact of serum CYFRA 21-1 in patients with advanced lung adenocarcinoma: a retrospective study. BMC Cancer. 2013;13:354 pubmed publisher
    ..However, it remains unknown whether pretreatment serum CYFRA 21-1 values (PCV) may also have prognostic implications in patients with advanced lung adenocarcinoma...